CervoMed (NASDAQ:CRVO – Get Free Report) and Briacell Therap (NASDAQ:BCTX – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.
Insider & Institutional Ownership
25.2% of CervoMed shares are held by institutional investors. Comparatively, 15.4% of Briacell Therap shares are held by institutional investors. 35.4% of CervoMed shares are held by insiders. Comparatively, 5.7% of Briacell Therap shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Profitability
This table compares CervoMed and Briacell Therap’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CervoMed | -290.72% | -59.15% | -53.64% |
| Briacell Therap | N/A | -479.97% | -182.26% |
Risk and Volatility
Valuation & Earnings
This table compares CervoMed and Briacell Therap”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CervoMed | $9.74 million | 8.19 | -$16.29 million | ($2.61) | -3.30 |
| Briacell Therap | N/A | N/A | -$4.79 million | ($83.18) | -0.16 |
Briacell Therap has lower revenue, but higher earnings than CervoMed. CervoMed is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current ratings and target prices for CervoMed and Briacell Therap, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CervoMed | 2 | 1 | 6 | 1 | 2.60 |
| Briacell Therap | 1 | 0 | 1 | 0 | 2.00 |
CervoMed currently has a consensus price target of $19.29, indicating a potential upside of 123.73%. Briacell Therap has a consensus price target of $320.00, indicating a potential upside of 2,320.57%. Given Briacell Therap’s higher probable upside, analysts plainly believe Briacell Therap is more favorable than CervoMed.
Summary
CervoMed beats Briacell Therap on 9 of the 14 factors compared between the two stocks.
About CervoMed
CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
About Briacell Therap
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
Receive News & Ratings for CervoMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CervoMed and related companies with MarketBeat.com's FREE daily email newsletter.
